← Back to Clinical Trials
Recruiting NCT06244472

NCT06244472 A New Generation of Magnetoencephalographs for High Speed Functional Brain Imaging

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06244472
Status Recruiting
Phase
Sponsor Hospices Civils de Lyon
Condition Mild Concussion
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2025-07-09
Primary Completion 2027-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Experiment 1: visual and auditory attention taskExperiment 2: language production and rest tasksExperiment 3: visuo-motor task

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2025-07-09 with a primary completion date of 2027-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal is to perform a first evaluation of the capabilities of a new generation of non-invasive magnetoencephalography whole head device using optically pumped magnetometers using Helium 4 as the sensitive element (OPM He4) to record brain magnetic activities. The investigators will record 1) healthy subjects stimulated with visual, auditory, somesthesic and motor stimuli and 2) athletes who suffered a mild concussion. The main hypothesis is that the OPM magnetoencephalographs (MEG) system will be able to detect brain activity. The secondary hypothesis is that the data recorded with the OPM MEG system will allow to reconstruct maps of the brain activity. To test the main hypothesis, they will compare the signal to noise ratio of brain activities between a classical MEG system and the new OPM He4 MEG. The secondary hypothesis will be tested through a comparison of the maps of brain activity obtained thanks to the data recorded with a classical MEG system and the new OPM He4 MEG.

Eligibility Criteria

Healthy volunteers: Inclusion Criteria: * Age 18 to 70 * Strongly motivated to participate to the study * Signed informed consent for the study Exclusion Criteria: * major cognitive deficit and unable to understand the instructions * previous neurology or psychiatric or sleep pathologies * Woman with a positive pregnancy test during the inclusion. * Subjects under guardianship, curatorship or safeguard of justice protection * Subjects deprived of their liberty * Subject not affiliated to a social security system. * Subject's refusal to be informed if an abnormality is detected during MEG and MRI scans * Subject with common contraindications to MEG and MRI examination : * Metal in the body incompatible with performance of the examination (pacemaker, implantable pump, neurostimulator, cochlear implant, auditory prothesis, metalic prothesis, intracerebral clip, implantable defibrillator, any metalic parts in the brain or upper part of the body, ventriculoperitoneal valve, dental appliance or steel pivot for root canal, ferromagnetic foreign body in the upper part of the upper part of the body) * Claustrophobia Subjects who suffered a mild concussion: Inclusion Criteria: * Male aged from 18 to 40 * Strongly motivated to participate to the study * Signed informed consent for the study * Mild concussion confirmed by the club doctor and a neurologist neurologist in the three weeks preceding the experiment Exclusion Criteria: * major cognitive deficit and unability to understand the instructions * previous neurology or psychiatric or sleep pathologies except mild concussion * Woman with a positive pregnancy test during the inclusion. * Subjects under guardianship, curatorship or safeguard of justice protection * Subjects deprived of their liberty * Subject not affiliated to a social security system * Subject's refusal to be informed if an abnormality is detected during MEG and MRI scans * Subject with common contraindications to MEG and MRI examination : * Metal in the body incompatible with performance of the examination (pacemaker, implantable pump, neurostimulator, cochlear implant, auditory prothesis, metalic prothesis, intracerebral clip, implantable defibrillator, any metalic parts in the brain or upper part of the body, ventriculoperitoneal valve, dental appliance or steel pivot for root canal, ferromagnetic foreign body in the upper part of the upper part of the body) * Claustrophobia

Contact & Investigator

Central Contact

Julien JUNG, MD

✉ julien.jung@chu-lyon.fr

📞 04.72.35.79.00

Principal Investigator

Julien JUNG, MD

PRINCIPAL INVESTIGATOR

Service d'Epilepsie et Explorations fonctionnelles neurologiques,Hôpital Neurologique P. Wertheimer, Groupement Hospitalier Est, HCL

Frequently Asked Questions

Who can join the NCT06244472 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Mild Concussion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06244472 currently recruiting?

Yes, NCT06244472 is actively recruiting participants. Contact the research team at julien.jung@chu-lyon.fr for enrollment information.

Where is the NCT06244472 trial being conducted?

This trial is being conducted at Bron, France, Lyon, France.

Who is sponsoring the NCT06244472 clinical trial?

NCT06244472 is sponsored by Hospices Civils de Lyon. The principal investigator is Julien JUNG, MD at Service d'Epilepsie et Explorations fonctionnelles neurologiques,Hôpital Neurologique P. Wertheimer, Groupement Hospitalier Est, HCL. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology